Macquarie **Equities Research**





The Asia Specialist

INDIA		
CRG IN	Underpe	rform
Price 20 Oct 11	Rs1	42.50
12-month target	Rs	117.00
Upside/Downside	%	-17.9
Valuation - PER	Rs	117.00
GICS sector	Capita	I Goods
Market cap	Rsm	91,425
30-day avg turnover	US\$m	1.5
Market cap	US\$m	1,860
Number shares on iss	ue m	641.6

Investment fundamentals

Year end 31 Mar		2011A	2012E	2013E	2014E
Revenue	bn	100.1	107.7	114.8	129.2
EBIT	bn	11.5	7.5	9.3	11.3
EBIT growth	%	2.5	-35.1	25.0	21.6
Recurring profit	bn	12.7	7.6	9.7	11.8
Reported profit	bn	9.3	5.8	7.4	8.9
Adjusted profit	bn	9.7	5.8	7.4	8.9
EPS adj	Rs	15.10	9.00	11.47	13.91
EPS adj growth	%	17.5	-40.4	27.4	21.3
PER adj	Х	9.4	15.8	12.4	10.2
Total DPS	Rs	2.42	1.57	2.01	2.43
Total div yield	%	1.7	1.1	1.4	1.7
ROA	%	17.2	9.8	11.3	12.4
ROE	%	33.5	16.4	18.9	20.4
EV/EBITDA	Х	6.9	9.4	7.9	6.6
Net debt/equity	%	5.2	5.6	3.4	-7.3
P/BV	Х	2.8	2.4	2.3	1.9

CRG IN rel BSE Sensex performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period.

Source: FactSet, Macquarie Research, October 2011 (all figures in INR unless noted)

Inderjeetsingh Bhatia

+91 22 6720 4087 inderjeet.bhatia@macquarie.com **Abhishek Bhandari**

+91 22 6720 4088 abhishek.bhandari@macquarie.com

20 October 2011 Macquarie Capital Securities India (Pvt) Ltd

Crompton Greaves India

Disappointment galore

Event

Expectations of revival were belied in CRG's 2QFY12 results. India business
has started facing problems and issues in overseas businesses remain
unresolved. We reduce our earnings estimates by ~15% and our target price
from Rs158 to Rs117. Retain Underperform.

Impact

- Problem creeping into India business: CRG's India power business had a 7% revenue decline (v/s 11% growth in 1QFY12). The consumer business continues to struggle with low growth of 4% and the industrial segment slowed down significantly to 9% in 2QFY12.
- No revival yet in overseas power systems: Contrary to expectations, the liquidation of inventories in overseas power systems has not taken place, resulting in an increase of Rs5.5bn (~50%) from FY11 levels. We note that the standalone company has been extending loans and advances to its overseas subsidiaries to help them meet their rising working capital needs.
- Margin revival unlikely to happen in a hurry: Competition continues to hurt India's power business (30% decline in transformer realisations since Jan'09). Interestingly, the recently won 765kV substation order from Powergrid has ~8% margins. Slow growth in the consumer business (~3% in 1HFY12) will continue to pressure margins.
- Management maintains FY12 guidance: Management maintains FY12 guidance of 10-12% revenue growth, with 8-10% EBITDA margin in the consolidated entity. It also plans to reduce its effective tax rate from 25% in FY11 to 15% in FY12E on an increase in R&D expenses from ~Rs1bn in FY11 to ~Rs2.5bn.
 - CRG paid Rs1bn of tax at overseas subsidiaries in 1HFY12 despite Rs3bn of losses, indicating that there is no tax offset across geographies. Even with 15% tax rate on higher R&D, FY12 tax outgoings will be at least Rs1.9bn (which has been paid in 1HFY12).
- Downside risks to consensus estimates: We believe there is downside risk to consensus EPS estimate of Rs11 in FY12, given that CRG clocked just Rs3.8 EPS in 1HFY12. We reduce our FY12-13E EPS by 15-16%.

Earnings and target price revision

• We cut our FY12-13E EPS estimates by 15-16%, mainly due to cuts in margins. We reduce our target price from Rs158 to Rs117 due to cut in EPS and target multiple from 15x to 13x, as uncertainty persists on the company meeting its guidance and the lower tax rate boosting its earnings.

Price catalyst

- 12-month price target: Rs117.00 based on a PER methodology.
- Catalyst: rising competition in India power and late revival in overseas power

Action and recommendation

 Investor confidence unlikely to return in a hurry: Operating performance for CRG needs to improve significantly for investor confidence to return to the stock. We retain our Underperform and revise our TP to Rs117.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com.au/disclosures.

Macquarie Research Crompton Greaves India


2QFY12 results - problems entering into India now


• Sharp revenue deceleration in India business: CRG standalone had 0% revenue growth in 2QFY12 due to a revenue decline of 7% in power systems. The consumer business continues to struggle, with low growth of 4%, while the industrial business slowed to 9% growth in 2QFY12.

Significant slowdown in India business... Fig 1

Fig 2 ...with sharp fall in margins across segments

■1QFY11 ■2QFY11 ■3QFY11 ■4QFY11 ■1QFY12 ■2QFY12





Source: Company data, Macquarie Research, October 2011

Source: Company data, Macquarie Research, October 2011

Overseas revenue growth partly aided by new subsidiaries: Overseas revenues at Rs12.5bn were up 32% YoY. However, these numbers included Rs940mn revenue contribution (€12mn from Emotron and US\$4mn from QEI Systems). Excluding these, the revenues increased by 22% in 2QFY12.

Fig 3 CRG - 2QFY12 consolidated result snapshot

Figs in Rs mn	2QFY11	2QFY12	YoY	1QFY11	QoQ	Comments
Net Revenues	23,979	27,055	13%	24,377	11%	Revenue growth partly driven by incorporation of QEI and Emotron
EBITDA	3,332	2,260	-32%	1,819	24%	
Net Financial Cost	49	102	111%	110	-7%	
Depreciation	458	726	59%	608	20%	
Other Income	228	215	-6%	151	42%	
PBT	3,054	1,646	-46%	1,253	31%	
Tax	920	463	-50%	475	-3%	
Reported PAT	2,136	1,167	-45%	795	47%	
EBITDA margin	13.9%	8.4%	-5.5%	7.5%	0.9%	Sequential improvement in margins due to lower losse in overseas subs
Order position						
Order book	71,160	71,200	0%	70,880	0%	Order book remains largely flat
Order inflow	27,119	22,600	-17%	17,040	33%	Reclassification of 1QFY12 orders led to growth sequentially

CRG - 2QFY12 standalone result snapshot

Figs in Rs mn	2QFY11	2QFY12	YoY	1QFY11	QoQ	Comments
Net Revenues	14,448	14,515	0%	14,688	-1%	Decline of 7% in power systems, meagre 4% growth in consumers
EBITDA	2,309	1,614	-30%	1,867	-14%	
Net Financial Cost	-7	1	-107%	14	-97%	
Depreciation	195	267	37%	286	-7%	
Other Income	193	168	-13%	157	7%	
PBT	2,314	1,515	-35%	1,723	-12%	
Tax	729	391	-46%	433	-10%	
Reported PAT	1,585	1,123	-29%	1,290	-13%	
EBITDA margin	16.0%	11.1%	-4.9%	12.7%	-1.6%	Margin dip primarily due to power systems

Macquarie Research Crompton Greaves India

> Inventory liquidation yet to take place: Liquidation of power inventory in overseas subsidiaries has not yet taken place in 2QFY12. Inventories for CRG have increased by Rs5.5bn (50%) from FY11 end to 1HFY12.

 Order inflow increases by 33% QoQ due to reclassification: The company reported order inflows of Rs22.6bn (Rs18.3bn in power and Rs4.3bn in industrial segments) in 2QFY12. CRG indicated that 1QFY12 was Rs17bn, and not Rs22bn as reported earlier, due to an error in classification.

Order inflow for CRG consolidated entity






Fig 6 Order book for CRG consolidated entity



Revising our estimates downwards by 15-16%


 Reducing our revenue estimates due to slowdown in India industrial and consumers segments: We reduce our revenue forecasts by 1.6-2% for FY12-13E to factor in slowdown in industrials segment and no pick-up in consumer segments in India. The industrial segment grew by 12% and consumer by 3% in 1HFY12.

We expect modest growth in India business... Fig 7



Source: Company data, Macquarie Research, October 2011


... as growth remains subdued across segments Fig 8



Source: Company data, Macquarie Research, October 2011


Macquarie Research Crompton Greaves India

Fig 9 We are building 8% revenue growth...



Source: Company data, Macquarie Research, October 2011


Fig 10 ... with 9.2% margin in consolidated entity



Source: Company data, Macquarie Research, October 2011


Reducing our margin forecasts to factor in continued competition in power systems: The
management continues to indicate high competition in domestic power systems, which led to a
margin decline from 12.1% in 1QFY12 to 11.1% in 2QFY12. New orders, like 765kV substation
order from Powergrid, have come at 8% margins.

Fig 11 We are building significant margin compression in India entity...



Source: Company data, Macquarie Research, October 2011

Fig 12 ... as we do not expect margin revival



Source: Company data, Macquarie Research, October 2011

 Reducing our EPS forecasts by 15-16%: Our EPS forecasts have been reduced by 15-16% for FY12-13 to factor in lower margins.

Fig 13 Reducing our FY12-13 consolidated EPS estimates by 15-16%

	FY	12E	FY	FY13E		% Change	
Net Revenues	old 109,389	new 107,688	old 117,160	new 114,794	12E -1.6%	13E -2.0%	
BITDA	11,248	9,945	13,701	11,863	-11.6%	-13.4%	
Net Income	6,766	5,772	8,712	7,356	-14.7%	-15.6%	
EPS	10.5	9.0	13.6	11.5	-14.7%	-15.6%	
EBITDA margin	10.3%	9.2%	11.7%	10.3%	-1.0%	-1.4%	
Source: Company data, Macqu	uarie Research, October 2	011					

20 October 2011 4

Macquarie Research Crompton Greaves India

Valuation – reducing our target price to Rs117


• Reducing our target price to Rs117: We reduce our target price from Rs158 to Rs117 to factor in a 15% earnings cut in FY12 and lower target multiple from 15x to 13x to factor in uncertainties in earnings and tax outgoings for the company.

Fig 14 Reducing our target price to Rs117

Segment	EV (Rs mn)	Value per share (Rs)	Comment
Core business	75,039	117	13x FY12 earnings
Total	75,039	117	

Source: Company data, Macquarie Research, October 2011

Fig 15 CRG – 1yr fwd PE chart



Source: Company data, Macquarie Research, October 2011

20 October 2011 5

Macquarie Research

Crompton Greaves In	ndia (C										
Quarterly Results		2Q/12A	3Q/12E	4Q/12E	1Q/13E	Profit & Loss		2011A	2012E	2013E	2014E
Revenue	m	25,845	26,922	31,229	25,255	Revenue	m	100,051	107,688	114,794	129,198
Gross Profit	m	9,433	9,826	11,399	9,218	Gross Profit	m	37,363	39,306	41,900	47,157
Cost of Goods Sold EBITDA	m m	16,412 2,387	17,095 2,486	19,831 2,884	16,037 2,610	Cost of Goods Sold EBITDA	m m	62,689 13,438	68,382 9,945	72,894 11,863	82,040 14,059
Depreciation	m	596	621	720	557	Depreciation	m	1,936	2,482	2,534	2,715
Amortisation of Goodwill	m	0	0	0	0	Amortisation of Goodwill	m	0	0	0	0
Other Amortisation	m	0	0	0	0	Other Amortisation	m	0	0	0	0
EBIT	m	1,791	1,866	2,164	2,052	EBIT	m	11,502	7,463	9,330	11,344
Net Interest Income Associates	m m	-128 0	-134 0	-155 0	-75 0	Net Interest Income Associates	m m	209 0	-534 0	-339 0	-317 0
Exceptionals	m	ő	ŏ	ŏ	ŏ	Exceptionals	m	-381	ŏ	ŏ	ŏ
Forex Gains / Losses	m	0	0	0	0	Forex Gains / Losses	m	0	0	0	0
Other Pre-Tax Income	m	168	175	203	165	Other Pre-Tax Income	m	999	699	748	803
Pre-Tax Profit Tax Expense	m m	1,831 -458	1,907 -477	2,212 -553	2,143 -536	Pre-Tax Profit Tax Expense	m m	12,329 -3,100	7,628 -1,907	9,739 -2,435	11,830 -2,957
Net Profit	m	1,373	1,430	1, 659	1,607	Net Profit	m	9,229	5,721	7,304	8,872
Minority Interests	m	12	13	15	11	Minority Interests	m	77	52	52	53
Reported Earnings Adjusted Earnings	m m	1,385 1,385	1,443 1,443	1,674 1,674	1,618 1,618	Reported Earnings Adjusted Earnings	m m	9,305 9,687	5,772 5,772	7,356 7,356	8,925 8,925
EPS (rep)		2.16	2.25	2.61	2.52	EPS (rep)		14.50	9.00	11.47	13.91
EPS (adj)	0/	2.16	2.25	2.61	2.52	EPS (adj) EPS Growth (adj)	0/	15.10	9.00 -40.4	11.47	13.91
EPS Growth yoy (adj)	%	-40.4	-40.4	-40.4	27.4	PE (rep)	% x	17.5 9.8	-40.4 15.8	27.4 12.4	21.3 10.2
						PE (adj)	x	9.4	15.8	12.4	10.2
EBITDA Margin	%	9.2	9.2	9.2	10.3	Total DPS		2.42	1.57	2.01	2.43
EBIT Margin	%	6.9	6.9	6.9	8.1	Total Div Yield	%	1.7	1.1	1.4	1.7
Earnings Split	%	24.0	25.0	29.0	22.0	Weighted Average Shares	m	642	642	642	642
Revenue Growth EBIT Growth	% %	7.6 -35.1	7.6 -35.1	7.6 -35.1	6.6 25.0	Period End Shares	m	642	642	642	642
Profit and Loss Ratios		2011A	2012E	2013E	2014E	Cashflow Analysis		2011A	2012E	2013E	2014E
Revenue Growth	%	9.5	7.6	6.6	12.5	EBITDA	m	13,438	9,945	11,863	14,059
EBITDA Growth	%	5.2	-26.0	19.3	18.5	Tax Paid	m	-3,100	-1,907	-2,435	-2,957
EBIT Growth Gross Profit Margin	% %	2.5 37.3	-35.1 36.5	25.0 36.5	21.6 36.5	Chgs in Working Cap Net Interest Paid	m	-5,859 0	-3,994 -534	-571 -339	-1,158 -317
EBITDA Margin	%	13.4	9.2	10.3	10.9	Other	m m	0	-554	-339	-317
EBIT Margin	%	11.5	6.9	8.1	8.8	Operating Cashflow	m	4,479	3,510	8,518	9,627
Net Profit Margin	%	9.2	5.3	6.4	6.9	Acquisitions	m	0	0	0	0
Payout Ratio	%	16.1	17.5	17.5	17.5	Capex	m	-7,627	-3,769	-4,018	-4,264
EV/EBITDA EV/EBIT	X	6.9 8.1	9.4 12.5	7.9 10.0	6.6 8.2	Asset Sales Other	m	0 1,333	0 803	0 881	0 964
EV/EBIT	Х	0.1	12.5	10.0	0.2	Investing Cashflow	m m	-6,295	-2,966	-3,137	-3,300
Balance Sheet Ratios						Dividend (Ordinary)	m	-1,555	-1,555	-1,555	-1,555
ROE	%	33.5	16.4	18.9	20.4	Equity Raised	m	0	0	0	0
ROA	%	17.2	9.8	11.3	12.4	Debt Movements	m	-306	0	0	0
ROIC Net Debt/Equity	% %	36.8 5.2	16.2 5.6	17.6 3.4	20.4 -7.3	Other Financing Cashflow	m m	0 -1,862	0 -1,555	0 -1,555	0 -1,555
Interest Cover Price/Book	X X	nmf 2.8	14.0 2.4	27.5 2.3	35.7 1.9	Net Chg in Cash/Debt	m	-3,654	-989	3,849	4,795
Book Value per Share	^	51.0	58.5	62.6	74.0	Free Cashflow	m	-3,148	-259	4,501	5,364
						Balance Sheet		2011A	2012E	2013E	2014E
						Cash	m	2,984	2,598	3,336	8,199
						Receivables	m	25,427	27,368	29,174	32,835
						Inventories Investments	m m	11,893 6,747	12,732 10,191	13,572 10,191	15,275 10,191
						Fixed Assets	m	18,314	19,601	21,085	22,633
						Intangibles	m	0	0	0	0
						Other Assets	m	7,379	7,736	8,068	8,741
						Total Assets	m	72,744	80,225	85,426	97,873
						Payables Short Term Debt	m m	29,595 0	31,853 0	33,956 0	38,216 0
						Long Term Debt	m	4,703	4,703	4,703	4,703
						Provisions	m	4,298	4,626	4,931	5,550
						Other Liabilities	m	1,244	1,348	1,481	1,642
						Total Liabilities	m	39,840	42,531	45,070 40,133	50,111
						Shareholders' Funds Minority Interests	m m	32,747 157	37,509 186	40,133 222	47,496 267
						Other	m	0	0	0	0
						Total S/H Equity Total Liab & S/H Funds	m m	32,904 72,744	37,695 80,225	40,356 85,426	47,763 97,873
All figures in INR unless noted.								. -,.	20,220	50, .20	2.,5.0
Source: Company data, Macqui	arie Res	earch, Octob	er 2011								

Macquarie Research Crompton Greaves India

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand

Outperform - return >3% in excess of benchmark return Neutral - return within 3% of benchmark return Underperform - return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

Macquarie - Asia/Europe

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

Macquarie First South - South Africa

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return
Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) - return >5% in excess of Russell 3000 index return

Neutral (Hold) - return within 5% of Russell 3000 index

Underperform (Sell)- return >5% below Russell 3000 index return

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk - Stock should be expected to move up or down 60-100% in a year - investors should be aware this stock is highly speculative.

High - stock should be expected to move up or down at least 40-60% in a year - investors should be aware this stock could be speculative.

Medium - stock should be expected to move up or down at least 30-40% in a year.

Low-medium – stock should be expected to move up or down at least 25-30% in a year.

Low - stock should be expected to move up or down at least 15-25% in a year.

* Applicable to Australian/NZ/Canada stocks only

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets

ROA Banks/Insurance = adjusted net profit /average

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 30 September 2011

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	57.35%	65.88%	56.94%	46.54%	74.68%	47.85% (for US coverage by MCUSA, 11.63% of stocks covered are investment banking cli	ients)
Neutral	31.99%	20.68%	31.94%	50.00%	23.42%	34.66% (for US coverage by MCUSA, 9.30% of stocks covered are investment banking clie	ents)
Underperform	10.66%	13.45%	11.11%	3.46%	1.90%	17.49% (for US coverage by MCUSA, 0.47% of stocks covered are investment banking clie	ents)

Company Specific Disclosures:

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures.

The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) (MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

General Disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie First South Securities (Pty) Limited; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise.

Country-Specific Disclaimers:

Australia: În Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered brokerdealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Services Authority (No. 193905). Germany: In Germany, research is issued and distributed by Macquarie Capital (Europe) Ltd, Niederlassung Deutschland, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). France: In France, research is issued and distributed by Macquarie Capital (Europe)

Macquarie Research Crompton Greaves India

Ltd, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Securities Ltd, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Securities Ltd. Japan: In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Securities Exchange Co. Ltd (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association and Financial Futures Association of Japan and Japan Securities Investment Advisers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, India, which is a SEBI registered Stock Broker having membership with National Stock Exchange of India Limited (INB231246738) and Bombay Stock Exchange Limited (INB011246734). Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: Information on securities/instruments that are traded in Taiwan is distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Thailand: In Thailand, research is issued and distributed by Macquarie Securities (Thailand) Ltd, a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member no. 28 of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03053&pageDiv=02. South Africa: In South Africa, research is issued and distributed by Macquarie First South Securities (Pty) Limited, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie First South Securities (Pty) Limited and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

Auckland	Bangkok	Calgary Tel: (1 403) 218 6650	Denver	Frankfurt	Geneva	Hong Kong
Tel: (649) 377 6433	Tel: (662) 694 7999		Tel: (303) 952 2800	Tel: (069) 509 578 000	Tel: (41) 22 818 7777	Tel: (852) 2823 3588
Jakarta	Johannesburg	Kuala Lumpur	London	Manila	Melbourne	Montreal
Tel: (62 21) 515 1818	Tel: (2711) 583 2000	Tel: (60 3) 2059 8833	Tel: (44 20) 3037 2000	Tel: (63 2) 857 0888	Tel: (613) 9635 8139	Tel: (1 514) 925 2850
Mumbai Tel: (91 22) 6653 3000	Munich Tel: (089) 2444 31800	New York Tel: (1 212) 231 2500	Paris Tel: (33 1) 7842 3823	Perth Tel: (618) 9224 0888	Seoul Tel: (82 2) 3705 8500	Shanghai Tel: (86 21) 6841 3355
Singapore Tel: (65) 6601 1111	Sydney Tel: (612) 8232 9555	Taipei Tel: (886 2) 2734 7500	Tokyo Tel: (81 3) 3512 7900	Toronto Tel: (1 416) 848 3500		

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, CapitalIQ and TheMarkets.com.

20 October 2011 8

Macquarie **Equities Research**





(632) 857 0899

Asia Research

heaH	of F	wiitw	Resea	arch

John O'Connell (Global Co - Head)	(612) 8232 7544
David Rickards (Global Co - Head)	(612) 8237 1159
Chris Hunt (Asia – Head)	(852) 3922 1119
Tim Smart (Asia – Deputy Head)	(852) 3922 3565

Automobiles/Auto Parts

Amit Mishra (India)	(9122) 6720 4084
Clive Wiggins (Japan)	(813) 3512 7856
Dan Lucas (Japan)	(813) 3512 6050
Michael Sohn (Korea)	(82 2) 3705 8644

Banks and Non-Bank Financials

Ismael Pili (Asia, Hong Kong)	(852) 3922 4774
Victor Wang (China)	(852) 3922 1479
Mudit Painuly (India)	(9122) 6720 4083
Suresh Ganapathy (India)	(9122) 6720 4078
Nicolaos Oentung (Indonesia)	(6221) 2598 8366
Alastair Macdonald (Japan)	(813) 3512 7476
Chan Hwang (Korea)	(822) 3705 8643
Matthew Smith (Malaysia, Singapore)	(65) 6601 0981
Alex Pomento (Philippines)	(632) 857 0899
Jemmy Huang (Taiwan)	(8862) 2734 7530
Passakorn Linmaneechote (Thailand)	(662) 694 7728

Conglomerates

Janet Lewis (Hong Kong)	(852) 3922 5417
Alex Pomento (Philippines)	(632) 857 0899

Consumer and Gaming

(852) 3922 3557
(852) 3922 4068
(9122) 6720 4084
(6221) 2598 8489
(813) 3512 7392
(822) 3705 8678
(632) 857 0899
(65) 6601 0840
(8862) 2734 7518
(662) 694 7993

Emerging Leaders

Jake Lynch (China, Asia)	(8621) 2412 9007
Jonathan Hsu (China, Hong Kong)	(852) 3922 4625
Saiyi He (Hong Kong)	(852) 3922 3585
Robert Burghart (Japan)	(813) 3512 7853
Makoto Egami (Japan)	(813) 3512 7879

Industrials

Janet Lewis (Asia)	(852) 3922 5417
Patrick Dai (China)	(8621) 2412 9082
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Juwon Lee (Korea)	(822) 3705 8661
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
David Gambrill (Thailand)	(662) 694 7753

Insurance

Scott Russell (Asia, China)	(852) 3922 3567
Chung Jun Yun (Korea)	(822) 2095 7222

Media and Internet

Jiong Shao (China, Hong Kong)	(852) 3922 3566
Steve Zhang (China, Hong Kong)	(852) 3922 3578
Nitin Mohta (India)	(9122) 6720 409
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899

Oil, Gas and Petrochemicals

James Hubbard (Asia)	(852) 3922 1226
Jal Irani (India)	(9122) 6720 4080
Polina Diyachkina (Japan)	(813) 3512 7886
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Trevor Buchinski (Thailand)	(662) 694 7829

Pharmaceuticals and Healthcare

Jonathan Hsu (Hong Kong)	(852) 3922 4625
Abhishek Singhal (India)	(9122) 6720 4086
Eunice Bu (Korea)	822) 2095 7223
Chinnarat Boonmahanark (Thailand)	(662) 694 7985

Property

Callum Bramah (Asia)	(852) 3922 4731
David Ng (China, Hong Kong)	(852) 3922 1291
Jeffrey Gao (China)	(8621) 2412 9026
Unmesh Sharma (India)	(9122) 6720 4092
Felicia Barus (Indonesia)	(6221) 2598 8480
Hiroshi Okubo (Japan)	(813) 3512 7433
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Alex Pomento (Philippines)	(632) 857 0899
Tuck Yin Soong (Singapore)	(65) 6601 0838
Elaine Cheong (Singapore)	(65) 6601 0839
Corinne Jian (Taiwan)	(8862) 2734 7522
Brandon Chen (Taiwan)	(8862) 2734 7518
Patti Tomaitrichitr (Thailand)	(662) 694 7727

Resources / Metals and Mining

Andrew Dale (Asia)	(852) 3922 3587
Graeme Train (China)	(8621) 2412 9035
Pelen Ji (China, Hong Kong)	(852) 3922 4741
Christina Lee (Hong Kong)	(852) 3922 3571
Rakesh Arora (India)	(9122) 6720 4093
Adam Worthington (Indonesia)	(852) 3922 4626
Polina Diyachkina (Japan)	(813) 3512 7886
Chak Reungsinpinya (Thailand)	(662) 694 7982

Technology

Jeffrey Su (Asia, Taiwan)	(8862) 2734 7512
Lisa Soh (China)	(852) 3922 1401
Nitin Mohta (India)	(9122) 6720 4090
Damian Thong (Japan)	(813) 3512 7877
David Gibson (Japan)	(813) 3512 7880
George Chang (Japan)	(813) 3512 7854
Jeff Loff (Japan)	(813) 3512 7851
Michiko Kakiya (Japan)	(813) 3512 7868
Yukihiro Goto (Japan)	(813) 3512 5984
Daniel Kim (Korea)	(822) 3705 8641
Andrew Chang (Taiwan)	(8862) 2734 7526
Daniel Chang (Taiwan)	(8862) 2734 7516
Kylie Huang (Taiwan)	(8862) 2734 7528

Telecoms

Nathan Ramier (Asia)	(813) 3512 7875
Lisa Soh (China, Hong Kong)	(852) 3922 1401
Riaz Hyder (Indonesia)	(6221) 2598 8486
Prem Jearajasingam	
(Malaysia, Singapore)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899
Joseph Quinn (Taiwan)	(8862) 2734 7519
Best Waiyanont (Thailand)	(662) 694 7993

Transport & Infrastructure

Janet Lewis (Asia, Japan)	(852) 3922 5417
Nicholas Cunningham (Japan)	(813) 3512 6044
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Utilities & Renewables	
Adam Worthington (Asia)	(852) 3922 4626
Jeff Evans (India)	(9122) 6720 4081
Prem Jearajasingam (Malaysia)	(603) 2059 8989

Alex Pomento (Philippines) Commodities

Jim Lennon	(4420) 3037 4271
Duncan Hobbs	(4420) 3037 4497
Bonnie Liu	(65) 6601 0144
Graeme Train	(8621) 2412 9035
Rakesh Arora	(9122) 6720 4093

Data Services

Andrea Dailly (Asia)	(852) 3922 4076
Eric Yeung	(852) 3922 4077
F	

Economics

Richard Gibbs (Australia)	(612) 8232 3935
Paul Cavey (China)	(852) 3922 3570
Renee Chen (Hong Kong, Taiwan)	(852) 3922 3597
Tanvee Gupta (India)	(9122) 6720 3455

Quantitative / CPG

Gurvinder Brar (Global)	(4420) 3037 4036
Viking Kwok (Asia)	(852) 3922 4735
Burke Lau (Asia)	(852) 3922 5494
Patrick Hansen (Japan)	(813) 3512 7876
Ayumu Kuroda (Japan)	(813) 3512 7569
Simon Rigney (Japan)	(813) 3512 7872

Strategy/Country

Michael Kurtz (Asia)	(852) 3922 1403
Peter Eadon-Clarke (Asia, Japan)	(813) 3512 7850
Jiong Shao (China, Hong Kong)	(852) 3922 3566
Rakesh Arora (India)	(9122) 6720 4093
Nicolaos Oentung (Indonesia)	(6121) 2598 8366
David Gibson (Japan)	(813) 3512 7880
Chan Hwang (Korea)	(822) 3705 8643
Kieran Calder (Malaysia)	(603) 2059 8992
Yeonzon Yeow (Malaysia)	(603) 2059 8982
Alex Pomento (Philippines)	(632) 857 0899
Conrad Werner (Singapore)	(65) 6601 0182
Daniel Chang (Taiwan)	(8862) 2734 7516
David Gambrill (Thailand)	(662) 694 7753

Find our research at

www.macquarie.com.au/research www.thomson.com/financial Macquarie: Thomson: Reuters: Bloomberg: www.knowledge.reuters.com MAC GO Factset: CapitalIQ

http://www.factset.com/home.aspx www.capitaliq.com www.themarkets.com TheMarkets.com Email macresearch@macquarie.com for access

Asia Sales

Regional Heads of Sales

Robin Black (Asia)	(852) 3922 2074
Chris Gray (ASEAN)	(65) 6601 0288
Peter Slater (Boston)	(1 617) 598 2502
Jeffrey Shiu (China & Hong Kong)	(852) 3922 2061
Thomas Renz (Geneva)	(41) 22 818 7712
Andrew Mouat (India)	(9122) 6720 4100
Kenneth Yap (Indonesia)	(6221) 515 1555
JJ Kim (Korea)	(822) 3705 8799
Jason Lee (Malaysia)	(603) 2059 8888
Chris Gould (Malaysia)	(603) 2059 8888
Gino C Rojas (Philippines)	(632) 857 0861
Greg Norton-Kidd (New York)	(1 212) 231 2527
Luke Sullivan (New York)	(1 212) 231 2507
Eric Roles (New York)	(1 212) 231 2559
Sheila Schroeder (San Francisco)	(1 415) 762 5001

Regional Heads of Sales cont'd

Miki Edelman (Taiwan)	(8862) 2734 7580
Angus Kent (Thailand)	(662) 694 7601
Michael Newman (Tokyo)	(813) 3512 7920
Angus Innes (UK/Europe)	(44) 20 3037 4841
Rob Fabbro (UK/Europe)	(44) 20 3037 4865
Sean Alexander (Generalist)	(852) 3922 2101

Regional Head of Distribution

Justin Crawford (Asia) (852) 3922 2065

Sales Trading

- · · · · · · · · · · · · · · · · · · ·	
Adam Zaki (Asia)	(852) 3922 2002
Yat Quan Tan (Hong Kong)	(852) 3922 2028
Phil Sellaroli (Japan)	(813) 3512 7837
Grace Lee (Korea)	(822) 3705 8601
Matthew Ryan (Singapore)	(65) 6601 0288

Sales Trading cont'd

_	
Mike Keen (Europe)	(44) 20 3037 4905
Chris Reale (New York)	(1 212) 231 2555
Marc Rosa (New York)	(1 212) 231 2555
Stanley Dunda (Indonesia)	(6221) 515 1555
Kenneth Cheung (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Isaac Huang (Taiwan)	(8862) 2734 7582
Dominic Shore (Thailand)	(662) 694 7707

Alternative Strategies

Convertibles - Roland Sharman	(852) 3922 2095
Depository Receipts - Seung-Jin Lee	(65) 6601 0203
Derivatives - Mark Holland	(852) 3922 2081
Structured Products - Andrew Terlich	(852) 3922 2013